Document is current
Any future updates will be listed below
-
Authors
Gujar, Shashi
Pol, Jonathan G.
Kumar, Vishnupriyan https://orcid.org/0000-0002-1800-243X
Lizarralde-Guerrero, Manuela https://orcid.org/0009-0004-0737-0941
Konda, Prathyusha https://orcid.org/0000-0002-6861-4442
Kroemer, Guido https://orcid.org/0000-0002-9334-4405
Bell, John C.
-
Funding
Funding for this research was provided by:
Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre
French Alliance for Life Sciences and Health
European Research Council
- License Information
-
More Information
Article History
Received: 10 May 2023
Accepted: 12 February 2024
First Online: 20 May 2024
Competing interests
: J.G.P. is named as an inventor on patents for cancer vaccination involving an oncolytic rhabdovirus. These patents have been licensed to Turnstone Biologics. G.K. holds research contracts with Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Osasuna Therapeutics, Samsara Therapeutics, Sanofi, Tollys and Vascage. G.K. consults for Reithera. G.K. is on the Board of Directors of the Bristol Myers Squibb Foundation France. G.K. is a scientific co-founder of everImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio. G.K. is on the scientific advisory boards of Hevolution, Institut Servier and Longevity Vision Funds. G.K. is the inventor of patents covering therapeutic targeting of aging, cancer, cystic fibrosis and metabolic disorders. J.C.B. is a co-founder of Turnstone Biologics and Esphera Synbio. J.C.B. holds multiple patents involving the development of OV-based therapeutics. J.C.B. is on the advisory boards of Transgene, Cytonus, Abalos and hCBioscience.
